There is absolutely no chance of them getting rid of the CII substance, it is needed for patients who aren't well controlled on non-opiate pain medicines. More stringency and guidelines imposed to doctors yes (although a negative for us), as well as, more emphasis on ADF formulations (huge positive for us).
This company is probably the best, if not one of the best OTC stocks there is and continues to improve. Increasing revenues every year, new partnerships, new generics, and fixing the flaws in our company as the FDA points them out, as necessary.
We will leave the pennies behind, on our own, or through a buyout. My target to sell has always been late 2017 to early 2018. My time frame still holds and I am even more confident in this stock then when I first invested, with all the new developments.
We are a baby company, with respect to the other BP's. Babies learn to crawl, then walk, then run.....We are about to enter the walking phase come end of this month. Mark this post.
GO ELTP. LONG AND STRONG AND ACCUMULATING ALL I CAN UNDER 20 cents.
News 
Market Data 
Discover 
AI
